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Lymphangioma refers to the local proliferation
of well-differentiated lymphatic tissue, which may
involve the head and neck regions, axilla, lungs,
pleura, bones, liver, spleen, and other regions,
except for the central nervous system.1 General-
ized lymphangiomatosis is a rare disease character-
ized by widespread abnormality of the lymphatic
system. Here, we report a female infant with 
generalized lymphangiomatosis presenting with
chylopericardium and intractable chylothorax.
Case Report
An 8-month-old, well-nourished female infant suf-
fered from nonproductive cough for 2 weeks. Mild
fever (body temperature, 38°C) and tachypnea
developed 1 day before admission. Chest roent-
genogram showed cardiomegaly (water-bottle
appearance) with a widening mediastinum and
increased infiltration over bilateral lung fields
(Figure 1A). Hemogram at admission was normal
except for thrombocytopenia (platelet count,
87,000/μL). Two-dimensional echocardiography
demonstrated a large fluid-filled pericardial space
without cardiac dysfunction; 58 mL of serosan-
guineous fluid was aspirated via pericardiocente-
sis. Analysis of the aspirate showed chylous fluid
(triglycerides, 134 mg/dL) without evidence of
infection or malignancy (acid-fast stain for three
sets and TB culture all negative; bacterial culture
negative; viral isolation negative; cytology revealed
only small lymphoid cells). The pericardial effu-
sion reaccumulated 4 hours later, so a pericardial
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window was created via pericardiectomy to prevent
tamponade. Biopsy of the pericardium showed
only fibrosis. Computed tomography of the chest
and abdomen showed an anterior mediastinal
mass, pericardial effusion, and splenomegaly in-
filtrated by hypoechoic nodules (Figure 1B and C).
Massive, bloody pericardial effusion was drain-
ed daily (200–640 mL/day). Complicating fac-
tors included bilateral lower leg edema and body
weight gain (2kg in 4 days) due to hypoalbumine-
mia and hypoglobulinemia (albumin 2.5 and
globulin 1.5 g/dL). Intravenous immunoglobulin
(IVIG, 1 g/kg/day for 1 day) and albumin (1 g/kg/
day for 2 days) were administered as adjuvant
treatment. Severe hypogammaglobulinemia (IgG,
85.1; IgA, 25.5; IgM, 66.7; IgE, 8.8 mg/dL) was
found 4 days after hospitalization. Exploratory
thoracotomy was performed to evaluate the ante-
rior mediastinal mass, and left parietal pleurectomy
was also performed during the same procedure in
an attempt to control the chylothorax. Then, the
anterior mediastinal tumor was excised in its en-
tirety. This soft tumor had an inverted T shape,
was 7 × 5 × 1 cm in size and was located in front
of and adherent to the upper pericardium and the
great vessels, encroaching on the brachiocephalic
vein. It was easily peeled off from the pericardium.
Multiple lymphatic channels were noted on the
tumor. The pericardium was partially excised 
in order to create a pericardiopleural window.
Microscopic examination of the resected thymic
tumor revealed numerous irregularly dilated vas-
cular spaces containing lymphatic fluid in the
thymic tissue (Figure 2), leading to the diagnosis
of thymic lymphangioma. Persistent chest tube
drainage was required and total parenteral nutri-
tion (TPN) and repeated component therapy of al-
bumin and IVIG were given. Enterobacter cloacae
bacteremia with septic shock and pulmonary
hemorrhage developed 3 weeks after the previ-
ous operation. Respiratory failure with complete
whiteout of the left lung field was found and the
patient was therefore intubated. A disseminated
intravascular coagulation laboratory profile with
thrombocytopenia (platelets, 21,000/dL) and ane-
mia (hemoglobin, 5.8 g/dL) was found despite
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Figure 1. (A) Initial chest radiograph shows cardiomegaly (water-bottle appearance) with widening upper mediastinum and
increased infiltration over bilateral lung fields. Computed tomography of the thorax and the abdomen shows (B) a relatively
enlarged thymus with heterogeneous enhancement (at the aortic arch level) and (C) an enlarged spleen with heterogeneous
enhancement and reticular pattern.
component therapy. Rapidly progressive he-
patosplenomegaly (liver, 9 cm; spleen, > 11 cm
palpable below the right costal margin) ensued.
Due to chest tube drainage dysfunction and ag-
gravation of the consumptive coagulopathy with
splenomegaly, laparotomy was performed with
splenectomy, left thoracotomy, and biopsy of lung.
Immunohistochemical studies demonstrated focal,
weak factor-VIII antigen staining of the cells lin-
ing the vascular channels of the spleen and lung.
Pathology confirmed lymphangiomatosis involv-
ing the thymus, spleen, and lung. Serial imaging
studies were characteristic of generalized lymphan-
giomatosis involving the neck, axilla, and the
pericardium. The postoperative course was un-
eventful, and the coagulopathy with thrombocy-
topenia resolved following splenectomy. TPN was
given with a low-fat, medium-chain triglyceride
(MCT) diet after extubation. Amoxicillin for post-
splenectomy chemoprophylaxis and a 3-month
course of daily subcutaneous injections of inter-
feron (IFN) alpha-2b at 3 million units/m2 were
given. There was no recurrence during follow-up
for 2 years by serial imaging studies. The only
side effect was mild fever during the initial 3 days
of treatment.
Discussion
Lymphangiomas are congenital malformations of
the lymphatic system that constitute 5.6% of all
benign tumors in infancy and childhood.2 They
grow very slowly and usually localize to one organ,
but occasionally involve several organs. According
to Noonan’s classification, generalized lymphan-
giomatosis is a subgroup of lymphangiectasia as-
sociated with diffuse lymphatic proliferation,
with a particular pattern of visceral involvement
and a progressive course.3 Factor VIII-related anti-
gen and CD31 are the most reliable markers for
identifying endothelial cells lining the lymphatic
spaces.4 Clinical manifestations depend on the
organ involved, and respiratory symptoms are
often the initial manifestation. The prognosis is
usually poor in patients with lung involvement.5
The most difficult issues in managing pa-
tients with lymphangiomas are intractable pleural
effusion and how to treat generalized lymphan-
giomatosis. Reported interventions for chyloperi-
cardium include pericardiocentesis, the creation
of a pericardial window, pericardiectomy, ligation
of the thoracic duct just above the diaphragm, and
the resection of pathologic structures (e.g. tumors).
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Figure 2. Pathology. (A) Photomicrograph of the thymus shows many irregular dilated vascular channels in thymic tissue
characteristic of Hassel’s corpuscles (arrowhead) and many lymphocytes in fat tissues (hematoxylin & eosin [H & E],
40×). (B) Photomicrograph of the thymus shows lymphangioma with numerous irregularly dilated vascular spaces con-
taining lymphatic fluid (arrow) in thymic tissue (H & E, 100×).
Ligation of the thoracic duct results in a good
prognosis; lymph will travel via an anastomosis
with the right lymphatic duct and by lymphati-
covenous communications with the azygos vein.6
Regarding chylothorax, current treatment is pal-
liative and involves drainage of the effusion
when there is significant respiratory distress. If
this fails to produce spontaneous resolution of
the effusion, aggressive treatments such as surgical
intervention and tetracycline pleurodesis are nec-
essary to avoid the complications of poor nutri-
tion, hypogammaglobulinemia, and lymphopenia
under persistent drainage of lymph, as well as to
improve the quality of life. Moreover, a low-fat
MCT diet can also be beneficial since it reduces
the rate of chyle formation.5 Regarding therapeu-
tic modalities for lymphangiomas, complete sur-
gical excision is the treatment of choice because
lymphangiomas rarely resolve spontaneously.
However, incomplete resections are common and
there is a high rate of recurrence. Several nonsurgi-
cal interventions have been proposed for patients
with unresectable lymphangiomas, including per-
cutaneous sclerotherapy (steroid, hypertonic saline,
ethanol, bleomycin, and OK-432 [Picibanil]),
systemic corticosteroids, radiation therapy, and
chemotherapy such as cyclophosphamide.7 How-
ever, the side effects of these modalities make them
unsuitable for most patients. Multiple organ in-
volvement makes percutaneous sclerotherapy
impossible. The long-term sequelae of systemic
corticosteroids and radiotherapy in children are
well known. Chemotherapeutic agents such as
cyclophosphamide have shown some promising
effects in slowing or stopping the growth rate of
most lymphangiomas,8 but the potential side 
effects are significant and include bone marrow
suppression, impaired liver function, hemorrhagic
cystitis, and late-onset malignancy.9
Disseminated lymphangiomatosis may be 
a proliferative disorder and it is not surprising
that IFN alpha plays a role in the treatment of
this disease. This cytokine has emerged as an 
important regulator of cell growth and differ-
entiation.10 Tazelaar et al reported the use of 
IFN in three patients with diffuse pulmonary
lymphangiomatosis. One of these patients was
stable after 20 months of treatment with IFN
alpha, one died of massive hemoptysis 18 months
after initiating IFN alpha treatment, and one did
not have sufficient follow-up.11 Margraf reported
a 10-year-old boy with thoracic lymphangiomato-
sis with unsuccessful use of IFN alpha in an attempt
to abate severe respiratory failure.12 Reinhardt 
et al reported two patients with lymphangiomato-
sis successfully treated by IFN alpha.7 Laverdiere 
et al reported a 3-year-old boy with generalized
lymphangiomatosis involving lung, ribcage, and
spleen. He showed significant clinical and ra-
diologic improvement after 28 months of IFN
alpha-2b treatment without significant toxicity.13
Whether this treatment is successful may depend
on the disease severity, the general condition, and
the dose and duration of IFN alpha treatment.
Our patient had the unusual initial presenta-
tion of cardiomegaly and extensive involvement
including the thymus, spleen, and lung, and highly
probable neck, axilla, and pericardium involve-
ment. Conservative treatment including drainage
of the pericardial and pleural fluid and lessening
of lymph production via TPN supplement was
ineffective. Complete surgical excision of the thy-
mus and the spleen were performed and adjuvant
IFN alpha-2b treatment was given for disseminated
involvement. Clinical and radiologic improvement
was noted after 3 months of treatment with IFN
alpha and no significant side effects occurred ex-
cept for a mild fever during the initial 3 days of
treatment. Her condition was stable for 2 years
following the completion of IFN alpha treatment.
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